AI assistant
Sending…
RESMED INC — Director's Dealing 2025
May 9, 2025
30071_dirs_2025-05-09_6dab5e65-bfa2-4b7a-a60b-64c5a7e35863.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RESMED INC (RMD)
CIK: 0000943819
Period of Report: 2025-05-07
Reporting Person: Farrell Michael J. (Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-05-07 | ResMed Common Stock | M | 8009 | $101.64 | Acquired | 463512 | Direct |
| 2025-05-07 | ResMed Common Stock | S | 8009 | $243.2268 | Disposed | 455503 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-05-07 | ResMed Common Stock Options | $101.64 | M | 8009 | Disposed | 2025-11-14 | ResMed Common Stock (8009) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| ResMed Common Stock | 2090 | Indirect |
Footnotes
F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
F2: Includes 30.3711 shares of ResMed stock purchased on April 30, 2025, through the ResMed Employee Stock Purchase Plan.
F3: This transaction was executed in multiple trades at prices ranging from $241.50 - $245.09. The price reported above reflects the weighted average sale price.
F4: Represents date options first become exercisable. Options vest 1/3 per year.
More from RESMED INC
Regulatory Filings
2026
May 26
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Feb 10
Regulatory Filings
2026
Feb 9
Director's Dealing
2026
Feb 6
Director's Dealing
2026
Feb 6
Director's Dealing
2026
Feb 3
Interim / Quarterly Report
2026
Jan 30
Earnings Release
2026
Jan 29